查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1397899

病毒載體和質粒 DNA 製造的全球市場：2024-2034

Viral Vectors & Plasmid DNA Manufacturing Market Report 2024-2034
出版日期: | 出版商: Visiongain | 英文 408 Pages | 商品交期: 最快1-2個工作天內

價格

預計到 2034 年，全球病毒載體和質粒 DNA 製造市場規模將以 17.5% 的複合年增長率增長。

生物技術的最新趨勢進一步強調了病毒載體和質粒的重要作用。 2023 年 1 月，生物製藥產業領先公司 Catalent 在比利時戈斯利開設了一家最先進的質粒 DNA (pDNA) 製造廠。 該設施不僅顯示了對質粒不斷增長的需求，而且顯示了對商業規模高效生產的需求。

本報告調查了全球病毒載體和質粒DNA 製造市場，提供了市場概況，分析了影響市場成長和市場機會的因素、市場規模的趨勢和預測，以及各個細分市場和地區的詳細資訊。我們編制了分析、競爭性報告景觀、主要公司簡介等等。

目錄

第 1 章報告概述

第 2 章執行摘要

第三章市場概述

  • 主要調查結果
  • 市場動態
    • 市場驅動因素
    • 市場限制因素
    • 市場機會
  • 新冠肺炎 (COVID-19) 影響分析
  • 波特五力分析
  • PEST分析

第四章病毒載體產能圖分析

  • 奇美電子的病毒載體製造能力
  • 無塵室套件設備：主要病毒載體製造商
  • 重建合約製造基礎設施的投資激增
  • 在細胞和基因治療領域投資和擴大 CMO/CDMO 設施

第五章病毒載體產生及產量分析

  • ATMP載體與製造平台
  • 與細胞和基因治療病毒載體相關的監管問題

第 6 章病毒載體的生產：製程經濟考量與挑戰

  • 製造技術的進步
  • 穩定的生產細胞系
  • 透過穩定的生產細胞系減少細胞毒性挑戰
  • 利用穩定生產細胞系的製程開發關鍵要素
  • 提高效率並降低成本：穩定生產細胞系在 CGT 生產中的貢獻
  • 什麼時候應該從瞬時轉染轉為穩定生產細胞系來生產 LVV？
  • 成本考慮
  • 監理期望

第七章重組腺相關病毒（rAAV）基因治療藥物生物製造的挑戰與進展

第八章病毒載體製作製程分析

  • 上游單元操作（細胞解凍和轉染擴增）
  • 下游單元運作（從精煉到收割）
  • 調整/穩定性和填充/整理
  • 病毒分析
  • 病毒載體產生：設備需求
  • 監理標準需求
  • 人力資源發展與需求

第 9 章病毒載體與質粒 DNA 製造市場分析：依載體型

  • 主要調查結果
  • 市場吸引力指數
  • 市場規模趨勢與預測
  • 腺病毒
  • 逆轉錄病毒
  • 質粒 DNA
  • AAV
  • 慢病毒
  • 其他載體
    • 市場規模趨勢與預測：按地區劃分
    • 市佔率：依地區劃分

第 10 章病毒載體與質粒 DNA 製造市場分析：依應用

  • 主要調查結果
  • 市場吸引力指數
  • 市場規模趨勢與預測
  • 反義和 RNAi
  • 基因治療
  • 細胞療法
  • 疫苗學
    • 市場規模趨勢與預測：按地區劃分
    • 市佔率：依地區劃分

第 11 章病毒載體與質粒 DNA 製造市場分析：依疾病分類

  • 主要調查結果
  • 市場吸引力指數
  • 市場規模趨勢與預測
  • 腫瘤
  • 遺傳性疾病
  • 傳染病
  • 其他
    • 市場規模趨勢與預測：按地區劃分
    • 市佔率：依地區劃分

第 12 章病毒載體與質粒 DNA 製造市場分析：依最終使用者

  • 主要調查結果
  • 市場吸引力指數
  • 市場規模趨勢與預測
  • 製藥和生物製藥公司
  • 研究院
    • 市場規模趨勢與預測：按地區劃分
    • 市佔率：依地區劃分

第 13 章病毒載體與質粒 DNA 製造市場分析：依工作流程

  • 主要調查結果
  • 市場吸引力指數
  • 市場規模趨勢與預測
  • 上游
  • 下游
    • 市場規模趨勢與預測：按地區劃分
    • 市佔率：依地區劃分

第 14 章病毒載體與質粒 DNA 製造市場分析：依地區

  • 主要調查結果
  • 市場規模趨勢與預測

第十五章北美病毒載體與質粒DNA製造市場分析

第十六章歐洲病毒載體與質粒DNA製造市場分析

第十七章亞太地區病毒載體與質粒 DNA 製造市場分析

第十八章拉丁美洲病毒載體與質粒 DNA 製造市場分析

第十九章中東與非洲病毒載體與質粒DNA製造市場分析

第20章公司簡介

  • 競爭狀況
  • 戰略展望
  • Amicus Therapeutics
  • Lonza Group Ltd
  • Merck KGaA
  • uniQure N.V.
  • Catalent Inc
  • Thermo Fisher Scientific Inc.
  • Charles River Laboratories
  • FUJIFILM Diosynth Biotechnologies
  • bluebird bio Inc
  • Aldevron
  • Addgene
  • Creative Biogene
  • VIVEbiotech
  • Recipharm AB
  • Waisman Biomanufacturing
  • VGXI, Inc.
  • Batavia Biosciences B.V.
  • WuXi AppTec
  • ATUM
  • Altogen Biosystems
  • GENEZEN
  • Yposkesi, Inc.
  • CEVEC Pharmaceuticals GmbH
  • Virovek
  • Advanced BioScience Laboratories, Inc (ABL)
  • Biovian Oy
  • BioNTech IMFS

第 21 章一般性評論/建議

  • Visiongain 概述
  • 給市場參與者的建議
Product Code: PHA1305

The global Viral Vectors and Plasmid DNA Manufacturing market is projected to grow at a CAGR of 17.5% by 2034 .

“The Viral Vectors and Plasmid DNA Manufacturing Market Report 2024-2034”: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Viral vectors and plasmids are instrumental in the field of biotechnology, especially in the context of advancements like CRISPR-Cas9 gene editing. They serve as indispensable vehicles for delivering genetic material with precision, enabling scientists to manipulate and modify genes for various purposes, from basic research to therapeutic interventions. Viral vectors, such as adeno-associated viruses (AAVs) and lentiviruses, have become central players in gene therapy, allowing for the targeted insertion of genetic material into host cells. Plasmids, on the other hand, are versatile circular pieces of DNA commonly used in molecular biology research to introduce foreign genes into cells or organisms. Their importance extends beyond gene editing to encompass a wide array of biotechnological applications, including vaccine development and protein production.

Recent developments in the biotechnology landscape further underscore the critical role of viral vectors and plasmids. In January 2023, Catalent, a prominent player in the biopharmaceutical industry, inaugurated a state-of-the-art plasmid DNA (pDNA) manufacturing facility in Gosselies, Belgium. This facility not only signifies the growing demand for plasmids but also the need for their efficient production at a commercial scale. Catalent's commitment to producing off-the-shelf plasmids to support cell and gene companies reflects the broader trend in the industry, where these genetic tools are in high demand. The integration of pDNA expertise in Gosselies with the clinical and commercial production of viral vectors for gene therapy, cell therapy, and mRNA across their network is a strategic move that ensures the continuity of the supply chain. It's a testament to the interdependence of these elements in the biotechnology ecosystem and their collective role in driving therapeutic innovations.

What Questions Should You Ask before Buying a Market Research Report?

  • How is the viral vectors and plasmid DNA manufacturing market evolving?
  • What is driving and restraining the viral vectors and plasmid DNA manufacturing market?
  • How will each viral vectors and plasmid DNA manufacturing submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2034?
  • How will the market shares for each viral vectors and plasmid DNA manufacturing submarket develop from 2024 to 2034?
  • What will be the main driver for the overall market from 2024 to 2034?
  • Will leading viral vectors and plasmid DNA manufacturing markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
  • How will the market shares of the national markets change by 2034 and which geographical region will lead the market in 2034?
  • Who are the leading players and what are their prospects over the forecast period?
  • What are the viral vectors and plasmid DNA manufacturing projects for these leading companies?
  • How will the industry evolve during the period between 2024 and 2034? What are the implications of viral vectors and plasmid DNA manufacturing projects taking place now and over the next 10 years?
  • Is there a greater need for product commercialisation to further scale the viral vectors and plasmid DNA manufacturing market?
  • Where is the viral vectors and plasmid DNA manufacturing market heading and how can you ensure you are at the forefront of the market?
  • What are the best investment options for new product and service lines?
  • What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the viral vectors and plasmid DNA manufacturing market today, and over the next 10 years:

  • Our 408-page report provides 166 tables, 183 charts /graphs exclusively to you
  • The report highlights key lucrative areas in the industry so you can target them - NOW
  • It contains in-depth analysis of global, regional and national sales and growth
  • It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the Viral Vectors and Plasmid DNA Manufacturing Market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2034 and other analyses reveal commercial prospects

  • In addition to revenue forecasting to 2034, our new study provides you with recent results, growth rates, and market shares
  • You will find original analyses, with business outlooks and developments
  • Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising viral vectors and plasmid DNA manufacturing prices and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, ""V" ", "L", "W" and "U" are discussed in this report.

Segments Covered in the Report:

Vector Type

  • Adenovirus
  • Retrovirus
  • Plasmid DNA
  • AAV
  • Lentivirus
  • Other Vectors

Application

  • Antisense and RNAi
  • Gene Therapy
  • Cell Therapy
  • Vaccinology

End-use

  • Pharma and Biopharma Companies
  • Research Institutes

Disease

  • Oncology
  • Genetic Disorders
  • Infectious Diseases
  • Others Diseases

Workflow

  • Upstream
  • Downstream

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 24 leading national markets:

North America

  • U.S
  • Canada

Europe

  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Sweden
  • Switzerland
  • Rest of Europe

Asia Pacific

  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Singapore
  • Taiwan
  • Rest of Asia Pacific

Latin America

  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America

MEA

  • GCC
  • South Africa
  • Rest of MEA

The report also includes profiles and for some of the leading companies in the Viral Vectors and Plasmid DNA Manufacturing Market, 2024 to 2034, with a focus on this segment of these companies' operations.

Leading companies profiled in the report:

  • Addgene
  • Advanced BioScience Laboratories, Inc. (ABL)
  • Aldevron
  • Altogen Biosystems
  • Amicus Therapeutics
  • ATUM
  • Batavia Biosciences B.V
  • BioNTech IMFS
  • Biovian Oy
  • bluebird bio Inc
  • Catalent Inc
  • CEVEC Pharmaceuticals GmbH
  • Charles River Laboratories
  • Creative Biogene
  • FUJIFILM Diosynth Biotechnologies
  • GENEZEN
  • Lonza
  • Merck KGaA
  • Recipharm AB
  • Thermo Fisher Scientific Inc
  • uniQure N.V
  • VGXI Inc
  • Virovek
  • VIVEbiotech
  • Waisman Biomanufacturing
  • WuXi AppTec
  • Yposkesi, Inc.

Overall world revenue for viral vectors and plasmid DNA manufacturing market, 2024 to 2034 in terms of value the market will surpass US$1,350 million in 2024, our work calculates. We predict strong revenue growth through to 2034. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the “Viral Vectors and Plasmid DNA Manufacturing Market, 2024 to 2034” report help you?

In summary, our 400+ page report provides you with the following knowledge:

  • Revenue forecasts to 2034 for Viral Vectors and Plasmid DNA Manufacturing Market, 2024 to 2034, with forecasts for vector types, application, and end-use, disease and workflow each forecast at a global and regional level - discover the industry's prospects, finding the most lucrative places for investments and revenues.
  • Revenue forecasts to 2034 for five regional and 24 key national markets - See forecasts for the Viral Vectors and Plasmid DNA Manufacturing Market 2024 to 2034 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Germany, UK, France, Spain, Italy, Sweden, Switzerland, China, India, Japan, Australia, South Korea, Singapore, Taiwan, Brazil, Mexico, Argentina, GCC, South Africa, and among other prominent economies.
  • Prospects for established firms and those seeking to enter the market - including company profiles for 27 of the major companies involved in the Viral Vectors and Plasmid DNA Manufacturing Market 2024 to 2034.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else

With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain's study is for everybody needing commercial analyses for the Viral Vectors and Plasmid DNA Manufacturing Market 2024 to 2034, market-leading companies. You will find data, trends and predictions.

Table of Contents

1 Report Overview

  • 1.1 Objectives of the Study
  • 1.2 Introduction to Viral Vectors and Plasmid DNA Manufacturing Market
  • 1.3 What This Report Delivers
  • 1.4 Why You Should Read This Report
  • 1.5 Key Questions Answered by This Analytical Report
  • 1.6 Who is This Report for?
  • 1.7 Methodology
    • 1.7.1 Market Definitions
    • 1.7.2 Market Evaluation & Forecasting Methodology
    • 1.7.3 Data Validation
      • 1.7.3.1 Primary Research
      • 1.7.3.2 Secondary Research
  • 1.8 Frequently Asked Questions (FAQs)
  • 1.9 Associated Visiongain Reports
  • 1.10 About Visiongain

2 Executive Summary

3 Market Overview

  • 3.1 Key Findings
  • 3.2 Market Dynamics
    • 3.2.1 Market Driving Factors
      • 3.2.1.1 Shaping the Future of Rare Disease Treatment with Viral Vector Solutions
      • 3.2.1.2 Viral Vectors and Plasmids Play a Pivotal Role in Enabling Precision and Breakthroughs in Biotechnology
      • 3.2.1.3 Investing in Progress Involves Capitalizing on the Viral Vector Revolution
    • 3.2.2 Market Restraining Factors
      • 3.2.2.1 Low Yields and Individual Optimization Hold Back Downstream Processes
      • 3.2.2.2 Viral Vector Demand Outpaces Capacity Growth Despite Increased Investments
    • 3.2.3 Market Opportunities
      • 3.2.3.1 Seizing the Viral Vector Opportunity for Enhanced Healthcare Access and Cost-efficient Therapies
      • 3.2.3.2 Advances in Genome Sequencing to Fuel Market Growth
      • 3.2.3.3 Rising Demand for Synthetic DNA Templates in RNA Medicine
  • 3.3 COVID-19 Impact Analysis
  • 3.4 Porter's Five Forces Analysis
    • 3.4.1 Bargaining Power of Suppliers
    • 3.4.2 Bargaining Power of Buyers
    • 3.4.3 Competitive Rivalry
    • 3.4.4 Threat from Substitutes
    • 3.4.5 Threat of New Entrants
  • 3.5 PEST Analysis

4 Viral Vector Production Capacity Mapping Analysis

  • 4.1 CMOs Capacity for Viral Vector Manufacturing
  • 4.2 Cleanroom Suites Facilities: Leading Viral Vector Manufacturers
  • 4.3 Surge of Investments Reshaping Contract Manufacturing Infrastructure.
  • 4.4 Investments and Expansions in CMO/CDMO Facilities in the Cell and Gene Therapy Sector

5 Viral Vector Production & Yield Analysis

  • 5.1 Introduction
  • 5.2 ATMP Vectors and Manufacturing Platforms
  • 5.3 Regulatory Challenges for Viral Vectors for Cell and Gene Therapy

6 Viral Vector Manufacturing: Process Economic Considerations and Challenges

  • 6.1 Technological Advances in Manufacturing
  • 6.2 Stable Producer Cell Lines
  • 6.3 Mitigating the Challenges of Cytotoxicity through Stable Producer Lines
  • 6.4 Key Factors in Process Development for the Utilization of Stable Producer Lines
  • 6.5 Enhancing Efficiency and Lowering Costs: The Contribution of Stable Producer Cell Lines in CGT Production
    • 6.5.1 Simplified Upstream Production
    • 6.5.2 Lower Costs for Reagents and Labour
    • 6.5.3 More Flexibility for Scale Up
  • 6.6 When is the Time to Switch from Transient Transfection to Stable Producer Cell Lines for LVV Manufacturing?
  • 6.7 Cost Considerations
  • 6.8 Regulatory Expectations

7 Challenges and Advances in Recombinant Adeno-Associated Viruses (rAAVs) Gene Therapy Biomanufacturing

  • 7.1 Introduction

8 Viral Vectors Production Process Analysis

  • 8.1 Introduction
  • 8.2 Upstream Unit Operations (Cell Thaw and Expansion Through Transfection)
  • 8.3 Downstream Unit Operations (Harvest Through Purification)
  • 8.4 Formulation/Stability and Fill/Finish
  • 8.5 Viral Analytics
  • 8.6 Viral Vector Production: Facilities Needs
  • 8.7 Regulatory Standard Needs
  • 8.8 Workforce Development and Needs

9 Viral Vectors and Plasmid DNA Manufacturing Market Analysis by Vector Type

  • 9.1 Key Findings
  • 9.2 Vector Type Segment: Market Attractiveness Index
  • 9.3 Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Vector Type
  • 9.4 Adenovirus
    • 9.4.1 Market Size by Region, 2024-2034 (US$ Million)
    • 9.4.2 Market Share by Region, 2024 & 2034 (%)
  • 9.5 Retrovirus
    • 9.5.1 Market Size by Region, 2024-2034 (US$ Million)
    • 9.5.2 Market Share by Region, 2024 & 2034 (%)
  • 9.6 Plasmid DNA
    • 9.6.1 Market Size by Region, 2024-2034 (US$ Million)
    • 9.6.2 Market Share by Region, 2024 & 2034 (%)
  • 9.7 AAV
    • 9.7.1 Market Size by Region, 2024-2034 (US$ Million)
    • 9.7.2 Market Share by Region, 2024 & 2034 (%)
  • 9.8 Lentivirus
    • 9.8.1 Market Size by Region, 2024-2034 (US$ Million)
    • 9.8.2 Market Share by Region, 2024 & 2034 (%)
  • 9.9 Other Vectors
    • 9.9.1 Market Size by Region, 2024-2034 (US$ Million)
    • 9.9.2 Market Share by Region, 2024 & 2034 (%)

10 Viral Vectors and Plasmid DNA Manufacturing Market Analysis by Application

  • 10.1 Key Findings
  • 10.2 Application Segment: Market Attractiveness Index
  • 10.3 Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Application
  • 10.4 Antisense and RNAi
    • 10.4.1 Market Size by Region, 2024-2034 (US$ Million)
    • 10.4.2 Market Share by Region, 2024 & 2034 (%)
  • 10.5 Gene Therapy
    • 10.5.1 Market Size by Region, 2024-2034 (US$ Million)
    • 10.5.2 Market Share by Region, 2024 & 2034 (%)
  • 10.6 Cell Therapy
    • 10.6.1 Market Size by Region, 2024-2034 (US$ Million)
    • 10.6.2 Market Share by Region, 2024 & 2034 (%)
  • 10.7 Vaccinology
    • 10.7.1 Market Size by Region, 2024-2034 (US$ Million)
    • 10.7.2 Market Share by Region, 2024 & 2034 (%)

11 Viral Vectors and Plasmid DNA Manufacturing Market Analysis by Disease

  • 11.1 Key Findings
  • 11.2 Disease Segment: Market Attractiveness Index
  • 11.3 Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Disease
  • 11.4 Oncology
    • 11.4.1 Market Size by Region, 2024-2034 (US$ Million)
    • 11.4.2 Market Share by Region, 2024 & 2034 (%)
  • 11.5 Genetic Disorders
    • 11.5.1 Market Size by Region, 2024-2034 (US$ Million)
    • 11.5.2 Market Share by Region, 2024 & 2034 (%)
  • 11.6 Infectious Diseases
    • 11.6.1 Market Size by Region, 2024-2034 (US$ Million)
    • 11.6.2 Market Share by Region, 2024 & 2034 (%)
  • 11.7 Other Diseases
    • 11.7.1 Market Size by Region, 2024-2034 (US$ Million)
    • 11.7.2 Market Share by Region, 2024 & 2034 (%)

12 Viral Vectors and Plasmid DNA Manufacturing Market Analysis by End-use

  • 12.1 Key Findings
  • 12.2 End-use Segment: Market Attractiveness Index
  • 12.3 Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by End-use
  • 12.4 Pharma and Biopharma Companies
    • 12.4.1 Market Size by Region, 2024-2034 (US$ Million)
    • 12.4.2 Market Share by Region, 2024 & 2034 (%)
  • 12.5 Research Institutes
    • 12.5.1 Market Size by Region, 2024-2034 (US$ Million)
    • 12.5.2 Market Share by Region, 2024 & 2034 (%)

13 Viral Vectors and Plasmid DNA Manufacturing Market Analysis by Workflow

  • 13.1 Key Findings
  • 13.2 Workflow Segment: Market Attractiveness Index
  • 13.3 Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Workflow
  • 13.4 Upstream
    • 13.4.1 Market Size by Region, 2024-2034 (US$ Million)
    • 13.4.2 Market Share by Region, 2024 & 2034 (%)
  • 13.5 Downstream
    • 13.5.1 Market Size by Region, 2024-2034 (US$ Million)
    • 13.5.2 Market Share by Region, 2024 & 2034 (%)

14 Viral Vectors and Plasmid DNA Manufacturing Market Analysis by Region

  • 14.1 Key Findings
  • 14.2 Regional Market Size Estimation and Forecast

15 North America Viral Vectors and Plasmid DNA Manufacturing Market Analysis

  • 15.1 Key Findings
  • 15.2 North America Viral Vectors and Plasmid DNA Manufacturing Market Attractiveness Index
  • 15.3 North America Viral Vectors and Plasmid DNA Manufacturing Market by Country, 2024, 2029 & 2034 (US$ Million)
  • 15.4 North America Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Country
  • 15.5 North America Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Vector Type
  • 15.6 North America Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Application
  • 15.7 North America Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by End-use
  • 15.8 North America Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Disease
  • 15.9 North America Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Workflow
  • 15.10 U.S. Viral Vectors and Plasmid DNA Manufacturing Market Analysis
  • 15.11 Canada Viral Vectors and Plasmid DNA Manufacturing Market Analysis

16 Europe Viral Vectors and Plasmid DNA Manufacturing Market Analysis

  • 16.1 Key Findings
  • 16.2 Europe Viral Vectors and Plasmid DNA Manufacturing Market Attractiveness Index
  • 16.3 Europe Viral Vectors and Plasmid DNA Manufacturing Market by Country, 2024, 2029 & 2034 (US$ Million)
  • 16.4 Europe Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Country
  • 16.5 Europe Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Vector Type
  • 16.6 Europe Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Application
  • 16.7 Europe Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by End-use
  • 16.8 Europe Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Disease
  • 16.9 Europe Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Workflow
  • 16.10 Germany Viral Vectors and Plasmid DNA Manufacturing Market Analysis
  • 16.11 France Viral Vectors and Plasmid DNA Manufacturing Market Analysis
  • 16.12 UK Viral Vectors and Plasmid DNA Manufacturing Market Analysis
  • 16.13 Italy Viral Vectors and Plasmid DNA Manufacturing Market Analysis
  • 16.14 Spain Viral Vectors and Plasmid DNA Manufacturing Market Analysis
  • 16.15 Sweden Viral Vectors and Plasmid DNA Manufacturing Market Analysis
  • 16.16 Switzerland Viral Vectors and Plasmid DNA Manufacturing Market Analysis
  • 16.17 Rest of Europe Viral Vectors and Plasmid DNA Manufacturing Market Analysis

17 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Analysis

  • 17.1 Key Findings
  • 17.2 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Attractiveness Index
  • 17.3 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market by Country, 2024, 2029 & 2034 (US$ Million)
  • 17.4 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Country
  • 17.5 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Vector Type
  • 17.6 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Application
  • 17.7 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by End-use
  • 17.8 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Disease
  • 17.9 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Workflow
  • 17.10 Japan Viral Vectors and Plasmid DNA Manufacturing Market Analysis
  • 17.11 China Viral Vectors and Plasmid DNA Manufacturing Market Analysis
  • 17.12 India Viral Vectors and Plasmid DNA Manufacturing Market Analysis
  • 17.13 Australia Viral Vectors and Plasmid DNA Manufacturing Market Analysis
  • 17.14 South Korea Viral Vectors and Plasmid DNA Manufacturing Market Analysis
  • 17.15 Singapore Viral Vectors and Plasmid DNA Manufacturing Market Analysis
  • 17.16 Taiwan Viral Vectors and Plasmid DNA Manufacturing Market Analysis
  • 17.17 Rest of Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Analysis

18 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Analysis

  • 18.1 Key Findings
  • 18.2 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Attractiveness Index
  • 18.3 Latin America Viral Vectors and Plasmid DNA Manufacturing Market by Country, 2024, 2029 & 2034 (US$ Million)
  • 18.4 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Country
  • 18.5 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Vector Type
  • 18.6 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Application
  • 18.7 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by End-use
  • 18.8 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Workflow
  • 18.9 Brazil Viral Vectors and Plasmid DNA Manufacturing Market Analysis
  • 18.10 Mexico Viral Vectors and Plasmid DNA Manufacturing Market Analysis
  • 18.11 Argentina Viral Vectors and Plasmid DNA Manufacturing Market Analysis
  • 18.12 Rest of Latin America Viral Vectors and Plasmid DNA Manufacturing Market Analysis

19 MEA Viral Vectors and Plasmid DNA Manufacturing Market Analysis

  • 19.1 Key Findings
  • 19.2 MEA Viral Vectors and Plasmid DNA Manufacturing Market Attractiveness Index
  • 19.3 MEA Viral Vectors and Plasmid DNA Manufacturing Market by Country, 2024, 2029 & 2034 (US$ Million)
  • 19.4 MEA Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Country
  • 19.5 MEA Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Vector Type
  • 19.6 MEA Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Application
  • 19.7 MEA Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by End-use
  • 19.8 MEA Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Disease
  • 19.9 MEA Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Workflow
  • 19.10 GCC Viral Vectors and Plasmid DNA Manufacturing Market Analysis
  • 19.11 South Africa Viral Vectors and Plasmid DNA Manufacturing Market Analysis
  • 19.12 Rest of MEA Viral Vectors and Plasmid DNA Manufacturing Market Analysis

20 Company Profiles

  • 20.1 Competitive Landscape, 2022
  • 20.2 Strategic Outlook
  • 20.1 Amicus Therapeutics
    • 20.1.1 Company Snapshot
    • 20.1.2 Company Overview
    • 20.1.3 Financial Analysis
      • 20.1.3.1 Net Revenue, 2017-2022
      • 20.1.3.2 R&D, 2017-2022
      • 20.1.3.3 Regional Market Shares, 2022
    • 20.1.4 Product Benchmarking
    • 20.1.5 Strategic Outlook
  • 20.2 Lonza Group Ltd
    • 20.2.1 Company Snapshot
    • 20.2.2 Company Overview
    • 20.2.3 Financial Analysis
      • 20.2.3.1 Net Revenue, 2017-2022
      • 20.2.3.2 R&D, 2017-2022
      • 20.2.3.3 Regional Market Shares, 2022
    • 20.2.4 Product Benchmarking
    • 20.2.5 Strategic Outlook
  • 20.3 Merck KGaA
    • 20.3.1 Company Snapshot
    • 20.3.2 Company Overview
    • 20.3.3 Financial Analysis
      • 20.3.3.1 Net Revenue, 2017-2022
      • 20.3.3.2 R&D, 2017-2022
      • 20.3.3.3 Regional Market Shares, 2022
    • 20.3.4 Product Benchmarking
    • 20.3.5 Strategic Outlook
  • 20.4 uniQure N.V.
    • 20.4.1 Company Snapshot
    • 20.4.2 Company Overview
    • 20.4.3 Financial Analysis
      • 20.4.3.1 Net Revenue, 2017-2022
      • 20.4.3.2 R&D, 2017-2022
      • 20.4.3.3 Regional Market Shares, 2022
    • 20.4.4 Product Benchmarking
    • 20.4.5 Strategic Outlook
  • 20.5 Catalent Inc
    • 20.5.1 Company Snapshot
    • 20.5.2 Company Overview
    • 20.5.3 Financial Analysis
      • 20.5.3.1 Net Revenue, 2017-2022
      • 20.5.3.2 R&D, 2017-2022
      • 20.5.3.3 Regional Market Shares, 2022
    • 20.5.4 Product Benchmarking
    • 20.5.5 Strategic Outlook
  • 20.6 Thermo Fisher Scientific Inc.
    • 20.6.1 Company Snapshot
    • 20.6.2 Company Overview
    • 20.6.3 Financial Analysis
      • 20.6.3.1 Net Revenue, 2017-2022
      • 20.6.3.2 R&D, 2017-2022
      • 20.6.3.3 Regional Market Shares, 2022
    • 20.6.4 Product Benchmarking
    • 20.6.5 Strategic Outlook
  • 20.7 Charles River Laboratories
    • 20.7.1 Company Snapshot
    • 20.7.2 Company Overview
    • 20.7.3 Financial Analysis
      • 20.7.3.1 Net Revenue, 2017-2022
      • 20.7.3.2 Regional Market Shares, 2022
    • 20.7.4 Product Benchmarking
    • 20.7.5 Strategic Outlook
  • 20.8 FUJIFILM Diosynth Biotechnologies
    • 20.8.1 Company Snapshot
    • 20.8.2 Company Overview
    • 20.8.3 Product Benchmarking
    • 20.8.4 Strategic Outlook
  • 20.9 bluebird bio Inc
    • 20.9.1 Company Snapshot
    • 20.9.2 Company Overview
    • 20.9.3 Financial Analysis
      • 20.9.3.1 Net Revenue, 2017-2022
      • 20.9.3.2 R&D, 2017-2022
    • 20.9.4 Product Benchmarking
    • 20.9.5 Strategic Outlook
  • 20.10 Aldevron
    • 20.10.1 Company Snapshot
    • 20.10.2 Company Overview
    • 20.10.3 Product Benchmarking
    • 20.10.4 Strategic Outlook
  • 20.11 Addgene
    • 20.11.1 Company Snapshot
    • 20.11.2 Company Overview
    • 20.11.3 Product Benchmarking
  • 20.12 Creative Biogene
    • 20.12.1 Company Snapshot
    • 20.12.2 Company Overview
    • 20.12.3 Product Benchmarking
  • 20.13 VIVEbiotech
    • 20.13.1 Company Snapshot
    • 20.13.2 Company Overview
    • 20.13.3 Product Benchmarking
    • 20.13.4 Strategic Outlook
  • 20.14 Recipharm AB
    • 20.14.1 Company Snapshot
    • 20.14.2 Company Overview
    • 20.14.3 Product Benchmarking
    • 20.14.4 Strategic Outlook
  • 20.15 Waisman Biomanufacturing
    • 20.15.1 Company Snapshot
    • 20.15.2 Company Overview
    • 20.15.3 Product Benchmarking
    • 20.15.4 Strategic Outlook
  • 20.16 VGXI, Inc.
    • 20.16.1 Company Snapshot
    • 20.16.2 Company Overview
    • 20.16.3 Product Benchmarking
    • 20.16.4 Strategic Outlook
  • 20.17 Batavia Biosciences B.V.
    • 20.17.1 Company Snapshot
    • 20.17.2 Company Overview
    • 20.17.3 Product Benchmarking
    • 20.17.4 Strategic Outlook
  • 20.18 WuXi AppTec
    • 20.18.1 Company Snapshot
    • 20.18.2 Company Overview
    • 20.18.3 Product Benchmarking
    • 20.18.4 Strategic Outlook
  • 20.19 ATUM
    • 20.19.1 Company Snapshot
    • 20.19.2 Company Overview
    • 20.19.3 Product Benchmarking
    • 20.19.4 Strategic Outlook
  • 20.20 Altogen Biosystems
    • 20.20.1 Company Snapshot
    • 20.20.2 Company Overview
    • 20.20.3 Product Benchmarking
  • 20.21 GENEZEN
    • 20.21.1 Company Snapshot
    • 20.21.2 Company Overview
    • 20.21.3 Product Benchmarking
    • 20.21.4 Strategic Outlook
  • 20.22 Yposkesi, Inc.
    • 20.22.1 Company Snapshot
    • 20.22.2 Company Overview
    • 20.22.3 Product Benchmarking
    • 20.22.4 Strategic Outlook
  • 20.23 CEVEC Pharmaceuticals GmbH
    • 20.23.1 Company Snapshot
    • 20.23.2 Company Overview
    • 20.23.3 Product Benchmarking
    • 20.23.4 Strategic Outlook
  • 20.24 Virovek
    • 20.24.1 Company Snapshot
    • 20.24.2 Company Overview
    • 20.24.3 Product Benchmarking
    • 20.24.4 Strategic Outlook
  • 20.25 Advanced BioScience Laboratories, Inc (ABL)
    • 20.25.1 Company Snapshot
    • 20.25.2 Company Overview
    • 20.25.3 Product Benchmarking
    • 20.25.4 Strategic Outlook
  • 20.26 Biovian Oy
    • 20.26.1 Company Snapshot
    • 20.26.2 Company Overview
    • 20.26.3 Product Benchmarking
    • 20.26.4 Strategic Outlook
  • 20.27 BioNTech IMFS
    • 20.27.1 Company Snapshot
    • 20.27.2 Company Overview
    • 20.27.3 Product Benchmarking
    • 20.27.4 Strategic Outlook

21 Conclusion and Recommendations

  • 21.1 Concluding Remarks from Visiongain
  • 21.2 Recommendations for Market Players

List of Tables

  • Table 1 Viral Vectors and Plasmid DNA Manufacturing Market Snapshot, 2022 & 2032 (US$ million, CAGR %)
  • Table 2 Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Region 2024-2034 (US$ Million, AGR%, CAGR%): ""V"" Shaped Recovery
  • Table 3 Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Region 2024-2034 (US$ Million, AGR%, CAGR%): ""U"" Shaped Recovery
  • Table 4 Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Region 2024-2034 (US$ Million, AGR%, CAGR%): ""W"" Shaped Recovery
  • Table 5 Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Region 2024-2034 (US$ Million, AGR%, CAGR%): ""L"" Shaped Recovery
  • Table 6 CMOs Capacity for Viral Vector Manufacturing
  • Table 7 Cleanroom Suites Facilities
  • Table 8 Investments and Expansions in CMO/CDMO Facilities in the Cell and Gene Therapy Sector
  • Table 9 Addressing Challenges and Technological Solutions
  • Table 10 Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Type, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 11 Adenovirus Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 12 Retrovirus Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 13 Plasmid DNA Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 14 AAV Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 15 Lentivirus Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 16 Other Vaccine Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 17 Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 18 Antisense RNAi Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 19 Bacterial Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 20 Cell Therapy Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 21 Vaccinology Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 22 Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 23 Oncology Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 24 Genetic Disorders Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 25 Infectious Diseases Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 26 Others Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 27 Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-use, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 28 Pharma and Biopharma Companies Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 29 Research Institutes Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 30 Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Workflow, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 31 Upstream Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 32 Downstream Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 33 Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 34 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Country, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 35 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Type, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 36 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 37 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-use, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 38 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 39 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast Workflow, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 40 U.S. Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 41 Canada Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 42 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Country, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 43 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Type, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 44 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 45 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-use, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 46 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 47 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast Workflow, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 48 Germany Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 49 France Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 50 UK Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 51 Italy Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 52 Spain Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 53 Sweden Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 54 Switzerland Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 55 Rest of Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 56 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Country, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 57 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Type, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 58 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 59 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-use, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 60 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 61 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast Workflow, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 62 Japan Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 63 China Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 64 India Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 65 Australia Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 66 South Korea Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 67 Singapore Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 68 Taiwan Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 69 Rest of Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 70 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Country, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 71 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Type, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 72 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 73 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-use, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 74 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast Workflow, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 75 Brazil Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 76 Mexico Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 77 Argentina Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 78 Rest of Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 79 MEA Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Country, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 80 MEA Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Type, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 81 MEA Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 82 MEA Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-use, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 83 MEA Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 84 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast Workflow, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 85 GCC Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 86 South Africa Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 87 Rest of MEA Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 88 Strategic Outlook
  • Table 89 Amicus Therapeutics: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 90 Amicus Therapeutics : Product Benchmarking
  • Table 91 AstraZeneca: Strategic Outlook
  • Table 92 Lonza Group Ltd: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 93 Lonza Group Ltd: Product Benchmarking
  • Table 94 Lonza Group Ltd: Strategic Outlook
  • Table 95 Merck KGaA: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 96 Merck KGaA: Product Benchmarking
  • Table 97 Merck: Strategic Outlook
  • Table 98 uniQure N.V.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 99 uniQure N.V. : Product Benchmarking
  • Table 100 uniQure N.V. : Strategic Outlook
  • Table 101 Catalent Inc: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 102 Catalent Inc: Product Benchmarking
  • Table 103 Catalent Inc: Strategic Outlook
  • Table 104 Thermo Fisher Scientific Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 105 Thermo Fisher Scientific Inc.: Product Benchmarking
  • Table 106 Thermo Fisher Scientific Inc.: Strategic Outlook
  • Table 107 Charles River Laboratories: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 108 Charles River Laboratories: Product Benchmarking
  • Table 109 Charles River Laboratories International Inc: Strategic Outlook
  • Table 110 FUJIFILM Diosynth Biotechnologies: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 111 FUJIFILM Diosynth Biotechnologies: Product Benchmarking
  • Table 112 FUJIFILM Diosynth Biotechnologies: Strategic Outlook
  • Table 113 bluebird bio Inc: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 114 bluebird bio Inc: Product Benchmarking
  • Table 115 bluebird bio Inc: Strategic Outlook
  • Table 116 Aldevron: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 117 Aldevron: Product Benchmarking
  • Table 118 Aldevron: Strategic Outlook
  • Table 119 Addgene: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 120 Addgene: Product Benchmarking
  • Table 121 Creative Biogene: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 122 Creative Biogene: Product Benchmarking
  • Table 123 Vivebiotech: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 124 VIVEbiotech: Product Benchmarking
  • Table 125 VIVEbiotech: Strategic Outlook
  • Table 126 Recipharm AB: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 127 Recifarm AB: Product Benchmarking
  • Table 128 Recipharm AB: Strategic Outlook
  • Table 129 Waisman Biomanufacturing: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 130 Waisman Biomanufacturing: Product Benchmarking
  • Table 131 Waisman Biomanufacturing: Strategic Outlook
  • Table 132 VGXI, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 133 VGXI, Inc. : Product Benchmarking
  • Table 134 VGXI, Inc.: Strategic Outlook
  • Table 135 Batavia Biosciences B.V.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 136 Batavia Biosciences B.V. : Product Benchmarking
  • Table 137 Batavia Biosciences B.V.: Strategic Outlook
  • Table 138 WuXi AppTec: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 139 Wuxi AppTec: Product Benchmarking
  • Table 140 Wuxi AppTec: Strategic Outlook
  • Table 141 ATUM: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 142 ATUM: Product Benchmarking
  • Table 143 ATUM: Strategic Outlook
  • Table 144 Altogen Biosystems: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 145 Altogen Biosystems: Product Benchmarking
  • Table 146 Genezen: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 147 Genezen: Product Benchmarking
  • Table 148 Genezen: Strategic Outlook
  • Table 149 Yposkesi, Inc: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 150 Yposkesi, Inc: Product Benchmarking
  • Table 151 Yposkesi, Inc: Strategic Outlook
  • Table 152 CEVEC Pharmaceuticals GmbH : Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 153 CEVEC Pharmaceuticals GmbH : Product Benchmarking
  • Table 154 CEVEC Pharmaceuticals GmbH: Strategic Outlook
  • Table 155 Virovek: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 156 Virovek : Product Benchmarking
  • Table 157 Virovek: Strategic Outlook
  • Table 158 ABL Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 159 ABL Inc.: Product Benchmarking
  • Table 160 ABL Inc.: Strategic Outlook
  • Table 161 Biovian Oy: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 162 Biovian Oy : Product Benchmarking
  • Table 163 Biovian Oy: Strategic Outlook
  • Table 164 BioNTech IMFS : Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 165 BioNTech IMFS: Product Benchmarking
  • Table 166 BioNTech IMFS: Strategic Outlook

List of Figures

  • Figure 1 Viral Vectors and Plasmid DNA Manufacturing Market Segmentation
  • Figure 2 Viral Vectors and Plasmid DNA Manufacturing Market by Vector Type: Market Attractiveness Index
  • Figure 3 Viral Vectors and Plasmid DNA Manufacturing Market by Application: Market Attractiveness Index
  • Figure 4 Viral Vectors and Plasmid DNA Manufacturing Market by End-use: Market Attractiveness Index
  • Figure 5 Viral Vectors and Plasmid DNA Manufacturing Market by Disease: Market Attractiveness Index
  • Figure 6 Viral Vectors and Plasmid DNA Manufacturing Market by Workflow: Market Attractiveness Index
  • Figure 7 Viral Vectors and Plasmid DNA Manufacturing Market Attractiveness Index by Region
  • Figure 8 Viral Vectors and Plasmid DNA Manufacturing Market: Market Dynamics
  • Figure 9 Viral Vectors and Plasmid DNA Manufacturing Market by Region, 2024-2034 (US$ Million, AGR %): "V" Shaped Recovery
  • Figure 10 Viral Vectors and Plasmid DNA Manufacturing Market by Region, 2024-2034 (US$ Million, AGR %): "U" Shaped Recovery
  • Figure 11 Viral Vectors and Plasmid DNA Manufacturing Market by Region, 2024-2034 (US$ Million, AGR %): "W" Shaped Recovery
  • Figure 12 Viral Vectors and Plasmid DNA Manufacturing Market by Region, 2024-2034 (US$ Million, AGR %): "L" Shaped Recovery
  • Figure 13 Viral Vectors and Plasmid Manufacturing Market: Porter's Five Forces Analysis
  • Figure 14 Viral Vectors and Plasmid Manufacturing Market: PEST Analysis
  • Figure 15 Viral Vectors and Plasmid DNA Manufacturing Market by Vector Type: Market Attractiveness Index
  • Figure 16 Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Type, 2024-2034 (US$ Million, AGR %)
  • Figure 17 Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Vector Type, 2024, 2029, 2034 (%)
  • Figure 18 Adenovirus Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 19 Adenovirus Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 20 Retrovirus Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 21 Retrovirus Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 22 Plasmid DNA Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 23 Plasmid DNA Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 24 AAV Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 25 AAV Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 26 Lentivirus Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 27 Letivirus Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 28 Other Vectors Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 29 Other Vectors Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 30 Viral Vectors and Plasmid DNA Manufacturing Market by Application: Market Attractiveness Index
  • Figure 31 Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2024-2034 (US$ Million, AGR %)
  • Figure 32 Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Application, 2024, 2029, 2034 (%)
  • Figure 33 Antisense RNAi Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 34 Antisense RNAi Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 35 Gene Therapy Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 36 Gene Therapy Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 37 Cell Therapy Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 38 Cell Therapy Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 39 Vaccinology Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 40 Vaccinology Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 41 Viral Vectors and Plasmid DNA Manufacturing Market by Disease: Market Attractiveness Index
  • Figure 42 Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2024-2034 (US$ Million, AGR %)
  • Figure 43 Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Disease, 2024, 2029, 2034 (%)
  • Figure 44 Oncology Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 45 Oncology Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 46 Genetic Disorders Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 47 Genetic Disorders Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 48 Infectious Diseases Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 49 Infectious Diseases Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 50 Others Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 51 Others Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 52 Viral Vectors and Plasmid DNA Manufacturing Market by End-use: Market Attractiveness Index
  • Figure 53 Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-use, 2024-2034 (US$ Million, AGR %)
  • Figure 54 Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by End-use, 2024, 2029, 2034 (%)
  • Figure 55 Pharma and Biopharma Companies Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 56 Pharma and Biopharma Companies Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 57 Research Institutes Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 58 Research Institutes Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 59 Viral Vectors and Plasmid DNA Manufacturing Market by Workflow: Market Attractiveness Index
  • Figure 60 Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Workflow, 2024-2034 (US$ Million, AGR %)
  • Figure 61 Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Workflow, 2024, 2029, 2034 (%)
  • Figure 62 Upstream Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 63 Upstream Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 64 Downstream Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 65 Downstream Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 66 Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Region 2024 and 2034 (Revenue, CAGR%)
  • Figure 67 Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Region 2024, 2029, 2034 (%)
  • Figure 68 Viral Vectors and Plasmid DNA Manufacturing Market by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 69 North America Viral Vectors and Plasmid DNA Manufacturing Market Attractiveness Index
  • Figure 70 North America Viral Vectors and Plasmid DNA Manufacturing Market by Region, 2024, 2029 & 2034 (US$ Million)
  • Figure 71 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
  • Figure 72 North America Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Country, 2024 & 2034 (%)
  • Figure 73 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Type, 2024-2034 (US$ Million, AGR %)
  • Figure 74 North America Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Vector Type, 2024 & 2034 (%)
  • Figure 75 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2024-2034 (US$ Million, AGR %)
  • Figure 76 North America Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Application, 2024 & 2034 (%)
  • Figure 77 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-use, 2024-2034 (US$ Million, AGR %)
  • Figure 78 North America Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by End-use, 2024 & 2034 (%)
  • Figure 79 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2024-2034 (US$ Million, AGR %)
  • Figure 80 North America Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Disease, 2024 & 2034 (%)
  • Figure 81 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Workflow 2024-2034 (US$ Million, AGR %)
  • Figure 82 North America Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Workflow, 2024 & 2034 (%)
  • Figure 83 U.S. Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 84 Canada Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 85 Europe Viral Vectors and Plasmid DNA Manufacturing Market Attractiveness Index
  • Figure 86 Europe Viral Vectors and Plasmid DNA Manufacturing Market by Region, 2024, 2029 & 2034 (US$ Million)
  • Figure 87 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
  • Figure 88 Europe Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Country, 2024 & 2034 (%)
  • Figure 89 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Type, 2024-2034 (US$ Million, AGR %)
  • Figure 90 Europe Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Vector Type, 2024 & 2034 (%)
  • Figure 91 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2024-2034 (US$ Million, AGR %)
  • Figure 92 Europe Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Application, 2024 & 2034 (%)
  • Figure 93 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-use, 2024-2034 (US$ Million, AGR %)
  • Figure 94 Europe Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by End-use, 2024 & 2034 (%)
  • Figure 95 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2024-2034 (US$ Million, AGR %)
  • Figure 96 Europe Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Disease, 2024 & 2034 (%)
  • Figure 97 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Workflow 2024-2034 (US$ Million, AGR %)
  • Figure 98 Europe Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Workflow, 2024 & 2034 (%)
  • Figure 99 Germany Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 100 France Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 101 UK Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 102 Italy Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 103 Spain Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 104 Sweden Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 105 Switzerland Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 106 Rest of Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 107 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Attractiveness Index
  • Figure 108 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market by Region, 2024, 2029 & 2034 (US$ Million)
  • Figure 109 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
  • Figure 110 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Country, 2024 & 2034 (%)
  • Figure 111 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Type, 2024-2034 (US$ Million, AGR %)
  • Figure 112 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Vector Type, 2024 & 2034 (%)
  • Figure 113 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2024-2034 (US$ Million, AGR %)
  • Figure 114 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Application, 2024 & 2034 (%)
  • Figure 115 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-use, 2024-2034 (US$ Million, AGR %)
  • Figure 116 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by End-use, 2024 & 2034 (%)
  • Figure 117 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2024-2034 (US$ Million, AGR %)
  • Figure 118 Europe Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Disease, 2024 & 2034 (%)
  • Figure 119 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Workflow 2024-2034 (US$ Million, AGR %)
  • Figure 120 North America Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Workflow, 2024 & 2034 (%)
  • Figure 121 Japan Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 122 China Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 123 India Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 124 Australia Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 125 South Korea Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 126 Singapore Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 127 Taiwan Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 128 Rest of Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 129 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Attractiveness Index
  • Figure 130 Latin America Viral Vectors and Plasmid DNA Manufacturing Market by Region, 2024, 2029 & 2034 (US$ Million)
  • Figure 131 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
  • Figure 132 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Country, 2024 & 2034 (%)
  • Figure 133 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Type, 2024-2034 (US$ Million, AGR %)
  • Figure 134 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Vector Type, 2024 & 2034 (%)
  • Figure 135 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2024-2034 (US$ Million, AGR %)
  • Figure 136 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Application, 2024 & 2034 (%)
  • Figure 137 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-use, 2024-2034 (US$ Million, AGR %)
  • Figure 138 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by End-use, 2024 & 2034 (%)
  • Figure 139 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Workflow 2024-2034 (US$ Million, AGR %)
  • Figure 140 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Workflow, 2024 & 2034 (%)
  • Figure 141 Brazil Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 142 Mexico Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 143 Argentina Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 144 Rest of Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 145 MEA Viral Vectors and Plasmid DNA Manufacturing Market Attractiveness Index
  • Figure 146 MEA Viral Vectors and Plasmid DNA Manufacturing Market by Region, 2024, 2029 & 2034 (US$ Million)
  • Figure 147 MEA Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
  • Figure 148 MEA Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Country, 2024 & 2034 (%)
  • Figure 149 MEA Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Type, 2024-2034 (US$ Million, AGR %)
  • Figure 150 MEA Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Vector Type, 2024 & 2034 (%)
  • Figure 151 MEA Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2024-2034 (US$ Million, AGR %)
  • Figure 152 MEA Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Application, 2024 & 2034 (%)
  • Figure 153 MEA Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-use, 2024-2034 (US$ Million, AGR %)
  • Figure 154 MEA Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Application, 2024 & 2034 (%)
  • Figure 155 MEA Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease 2024-2034 (US$ Million, AGR %)
  • Figure 156 MEA Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Disease, 2024 & 2034 (%)
  • Figure 157 MEA Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Workflow 2024-2034 (US$ Million, AGR %)
  • Figure 158 MEA Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Workflow, 2024 & 2034 (%)
  • Figure 159 G